<vrts class="jjsdsl"></vrts>
南宫NG28
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
Email Alert
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
Email Alert
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
搜索
Be the most trusted biotech company
Press Release
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2019-06-10
Henlius Attends BIO 2019
2019-04-25
Henlius Trastuzumab HLX02 Filed New Drug Application
2019-03-22
Global Clinical Medicine Affairs Department Needs You to Join!
2019-03-19
The 2nd Combination Immunotherapy of Henlius Received Notification of Acceptance
2019-03-01
Official Announcement! Mr. WenjieZhang is Appointed as SVP and CCO of Henlius
2019-02-25
Henlius Receives NMPA Approval for Its First Product HLX01 –The Beginning of a New Era for Biosimilar
2019-02-12
New progress! Henlius HLX22 Received Clinical Approval from NMPA
2019-01-29
Henlius Completed Phase 1/2 Study of Its Rituximab Injection for Rheumatoid Arthritis
2019-01-24
Henlius Adalimumab Received Acceptance of New Drug Application
1
...
55
56
57
58
59
60
